文献速递病毒性肝炎

HBeAg阳性患者停用替诺福韦后乙肝病毒复发较恩替卡韦更早且更频繁

Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients.
PubMed 文献 · J Infect Dis · 2022-01-01

研究纳入205例停用恩替卡韦和111例停用富马酸替诺福韦二吡呋酯的HBeAg阳性无肝硬化患者,发现停用替诺福韦者病毒学和临床复发率显著高于停用恩替卡韦者,且治疗期间HBeAg未血清学转换及治疗结束时HBcrAg水平较高是复发的重要预测因素。

要点

  • 停用替诺福韦的患者病毒学和临床复发率显著高于停用恩替卡韦的患者。
  • 治疗期间HBeAg消失但未产生抗-HBe的患者停药后复发和HBeAg血清学逆转率更高。
  • 治疗结束时HBcrAg水平与乙肝病毒复发和HBeAg血清学逆转独立相关。

核心结论

  • 替诺福韦治疗、治疗期间HBeAg消失未血清学转换以及治疗结束时HBcrAg水平较高是HBeAg阳性患者停用恩替卡韦或替诺福韦后乙肝病毒复发的显著预测因素。

研究设计与样本

  • 研究招募了205例和111例分别停用恩替卡韦或富马酸替诺福韦二吡呋酯至少6个月的HBeAg阳性无肝硬化患者。

主要发现

  • 在整个队列、治疗期间发生HBeAg血清学转换的患者以及倾向评分匹配的患者中,停用替诺福韦者病毒学和临床复发率均显著高于停用恩替卡韦者。
  • 多因素分析显示,在整个队列和亚组分析中,替诺福韦与病毒学和临床复发独立相关。
  • 治疗期间HBeAg消失但未产生抗-HBe抗体的患者,停药后乙肝病毒复发率和HBeAg血清学逆转率显著高于治疗期间发生HBeAg血清学转换的患者。
  • 治疗结束时HBcrAg水平在所有患者和治疗期间发生HBeAg血清学转换的患者中与乙肝病毒复发和HBeAg血清学逆转独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study investigated the incidence and predictors of hepatitis B virus (HBV) relapse in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who discontinued entecavir (ETV) or tenofovir disoproxil fumarate (TDF). METHODS: A total of 205 and 111 HBeAg-positive patients without cirrhosis who had stopped ETV or TDF treatment, respectively, for at least 6 months were recruited. RESULTS: In the entire cohort, patients with HBeAg seroconversion during treatment, and propensity score-matched patients, those who discontinued TDF had significantly higher rates of virological and clinical relapse than patients who discontinued ETV therapy. Multivariate analysis identified that TDF was independently associated with virological and clinical relapse in the entire cohort and subgroup analysis. Patients with HBeAg loss without anti-HBe antibody formation during treatment had significantly higher rates of off-therapy HBV relapse and HBeAg seroreversion than patients with HBeAg seroconversion during treatment. The hepatitis B core-related antigen (HBcrAg) level at end of treatment (EOT) was independently associated with HBV relapse and HBeAg seroreversion in all patients and patients with HBeAg seroconversion during treatment. CONCLUSIONS: TDF therapy, HBeAg loss without seroconversion during treatment, and higher HBcrAg levels at EOT are significant predictors of HBV relapse in HBeAg-positive patients who discontinued ETV or TDF.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chen CH, Peng CY, Kuo YH, et al. Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients. J Infect Dis. 2022. PMID: 34894128. doi:10.1093/infdis/jiab596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。